# Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

> **NCT04692103** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Washington** · enrollment: 2 (actual)

## Conditions studied

- Estrogen Receptor Positive
- Primary or Recurrent Breast Carcinoma
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **DRUG:** F-18 16 Alpha-Fluoroestradiol
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Computed Tomography
- **DRUG:** Fludeoxyglucose F-18
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Computed Tomography
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT04692103
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-10
- **Primary completion:** 2021-10-01
- **Final completion:** 2041-04-30
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2026-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04692103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04692103, "Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04692103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*